# From design to formulation of peptide building blocks for nanotheranostic applications: a synergistic multidisciplinary investigation

Alice Am, Laura Trapiella-Alfonso, Camille Lescot, Bich-Thuy Doan, Fanny D'orlyé, Anne Varenne

<figure><img src="image_1.png" /></figure>

## ► To cite this version:

Alice Am, Laura Trapiella-Alfonso, Camille Lescot, Bich-Thuy Doan, Fanny D'orlyé, et al.. From design to formulation of peptide building blocks for nanotheranostic applications: a synergistic multidisciplinary investigation. Comptes Rendus. Chimie, 2025, 28 (G1), pp.239-263. 10.5802/crchim.372. hal-05355529

HAL Id: hal-05355529

https://hal.science/hal-05355529v1

Submitted on 8 Nov 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_3.png" /></figure>

ACADÉMIE
DES SCIENCES
INSTITUT DE FRANCE

# Comptes Rendus
Chimie

Alice Am, Laura Trapiella-Alfonso, Camille Lescot, Bich-Thuy Doan, Fanny d'Orlyé and Anne Varenne

From design to formulation of peptide building blocks for nanotheranostic applications: a synergistic multidisciplinary investigation

Volume 28 (2025), p. 239-263

Online since: 7 March 2025

https://doi.org/10.5802/crchim.372

<figure><img src="image_4.png" /></figure>

This article is licensed under the
CREATIVE COMMONS ATTRIBUTION 4.0 INTERNATIONAL LICENSE.
http://creativecommons.org/licenses/by/4.0/

<figure><img src="image_5.png" /></figure>

The Comptes Rendus. Chimie are a member of the
Mersenne Center for open scientific publishing
www.centre-mersenne.org — e-ISSN: 1878-1543
Account

# From design to formulation of peptide building blocks for nanotheranostic applications: a synergistic multidisciplinary investigation

Alice Am<sup>a</sup>, Laura Trapiella-Alfonso<sup>®, a</sup>, Camille Lescot<sup>®, a</sup>, Bich-Thuy Doan<sup>®, a</sup>, Fanny d'Orlyé<sup>®, a</sup> and Anne Varenne<sup>®, *, a</sup>

**Abstract.** This study presents the journey of a collaborative project for the development of biocompat-
ible nanotheranostic tools, based on peptide self-assembling nanostructures. The peptide sequences
were designed to combine smart drug delivery and imaging properties. For this purpose, the selected
sequences present: (1) an amphiphilic character for self-assembling properties, efficient hydrophobic
drugs encapsulation and efficient biodistribution; (2) a pH-sensitive self-assembly for drug delivery
under pH modification in the environment of cancer cells; (3) a receptor-targeting motif within the
peptide sequence, overexpressed by certain cancer cells, for specific and controlled delivery of the ac-
tive ingredient to tumors; (4) accessible functions for further functionalization with a contrast agent
for diagnosis. These sequences were first synthesized in a continuous flow to provide a rapid and ver-
satile synthetic process, while lowering reactant consumption, and the synthetic route was optimized
through the development of an electrokinetic method coupled to UV-visible detection (CE-UV) and
mass spectrometry (CE-MS) that allowed a powerful physicochemical characterization in terms of se-
quence identification and purity. Few pertinent peptide sequences were then functionalized with a
complex of gadolinium to generate Magnetic Resonance Imaging (MRI) properties, and this function-
alization step was also optimized and controlled by CE-MS. The formulation procedure was then de-
veloped by a deep physicochemical characterization of the peptide nanostructures and the combina-
tion of analytical and physical methods to highlight the mechanisms generating the quick reversible
self-assembly. Finally, MRI imaging studies on both monomers and nanostructures evidenced a good
MRI contrast with properties adapted for a short half-life time.

**Keywords.** Short synthetic amphiphilic peptides, Continuous flow SPPS peptide synthesis aided by CE-MS, Peptide self-assembly, Physicochemical characterization, MRI, Theranostic agents.

**Funding.** CNRS MITI Défi Organisation (AAP 2021, Pepthera), IPGG Microfluidique Carnot Institute (Call 2020, PSL: C21-14-2021-033).

Manuscript received 28 September 2024, revised 13 November 2024 and 5 December 2024, accepted 9 December 2024.

**1. Introduction**

Currently, the treatment of most diseases uses drugs,
in the form of formulation of active pharmaceuti-
cal ingredients. However, their therapeutic effect

is often significantly reduced due to low bioavail-
ability, linked to poor pharmacokinetics generated
by low chemical stability, solubility, or even too
rapid metabolism leading to premature elimination
of the drug, therefore requiring several doses [1,2].
Furthermore, the absence of targeting specific ar-
eas (tumors, inflammatory sites, etc.) leads to
random drug delivery, which can cause significant

<footnote><sup>a</sup> Institute of Chemistry for Life & Health Sciences (iCLeHS), Chimie ParisTech, PSL University, CNRS 8060, 75005, Paris, France</footnote>

<footnote>E-mail: anne.varenne@chimieparistech.psl.eu (A. Varenne)</footnote>

<footnote>* Corresponding author</footnote>
side effects and result in poor patient treatment
tolerance.

For more than three decades, numerous nano-
materials have been developed as drug delivery
systems. Such nanovectors can combine several
functionalities and physicochemical properties to
improve pharmacokinetics compared to the non-
encapsulated drug [3]. Among these functionalities,
the integration of imaging probes is of significance
in designing theranostic nanoobjects, providing si-
multaneous therapeutic properties and monitoring
for image-guided therapy. Thus, the biodistribution
of the nanovector can be studied in a non-invasive
manner [4]. Furthermore, the addition of specific
targeting ligands on the nanoobject enable the de-
tection of diseases at an early stage and would in-
crease the chance of recovery thanks to early diag-
nosis [5]. This specific targeting is also relevant for
targeted delivery of anticancer drugs into tumors,
since these active molecules are generally cytotoxic,
thus limiting toxicity to healthy cells.

Despite the development of numerous theranostic nanoobjects, their translation into clinical practice remains difficult due to concerns about the safety of these products. Indeed, the elimination of nanoparticles in the body strongly depends on their physicochemical properties, i.e., size, shape, surface charge, and the nature of the material [6]. Thus, there is a growing interest in biodegradable and biocompatible nanomaterials, formed from natural building blocks, such as nanostructures based on peptide self-assembly [7]. Peptides are versatile biopolymers which present a great diversity of sequences, including sequences capable of self-assembling into nanoarchitectures of various structures. The peptide sequence can be controlled during the synthesis and the presence of reactive chemical functions on the peptide facilitates its functionalization with targeting ligands, imaging probes or therapeutic molecules [8]. Peptide self-assemblies can also lead to intelligent nanoobjects sensitive to endogenous or exogenous stimuli. For example, pH variations in the body are often associated with pathologies, such as cancer. Thus, peptides could be designed to self-assemble reversibly depending on the pH [9]. For delivery of anticancer drugs, the disassembly of the nanostructure in response to a variation of pH would trigger the release of the active molecule. Specific nanostructures based on peptide self-assembly were

developed for the targeted delivery of anticancer
drugs, thanks to peptides specifically targeting re-
ceptors overexpressed by certain tumors, and con-
trolled by an endogenous stimulus, including pH as
well as the presence of reactive oxygen species or en-
zymatic activity [10]. Contrast agents based on pep-
tide self-assembly are also described, particularly for
Magnetic Resonance Imaging (MRI), with better per-
formances than molecular MRI probes [11]. Nanoob-
jects have already been studied for drug delivery [12]
or as imaging probes [13], but a combination of the
two characteristics is still in its infancy.

Few nanotheranostic agents based on self-assembled peptides were designed to be used simultaneously as a drug carrier and an imaging probe. In these use cases, the peptide sequences contain an RGD (R = Arg; G = Gly; D = Asp) or an octreotide motif to target the αvβ3 integrin somatostatin receptors, respectively, overexpressed by tumor cells in certain types of cancers [14,15]. An MRI probe was also conjugated to the peptide for in vivo tracking of nanoobjects, with the aim of improving the contrast of images generated in MRI. However, the nanoobjects described in these examples are not stimulus-responsive and the delivery of drugs is carried out by sustained release.

Therefore, challenges persist in the design of nan-
otheranostic tools capable of actively targeting cer-
tain areas. First, sensitivity of the nanoobject to an
endogenous stimulus is essential for real control of
drug delivery in the targeted area. Thus, the disas-
sembly of the structure under a stimulus would trig-
ger the release of the active ingredient and the pep-
tides serving as building blocks will be quickly elimi-
nated. Furthermore, the integration of the MRI probe
into the nanoobject must be done in a way that does
not interfere with the peptide self-assembly and the
interaction between the targeting ligand and its re-
ceptor, while maintaining the imaging properties of
the probe.

The development of self-assembled nanoobjects
providing all the aforementioned properties relies
heavily on the design of the peptide sequence serv-
ing as the basic block. Among the different pep-
tide sequences having self-assembly properties, am-
phiphilic peptides were selected as they can form
micelle-type structures, suitable for the encapsu-
lation of hydrophobic therapeutic molecules [16].
These amphiphilic sequences should be further
designed for smart drug delivery, coupling both a
targeting motif to a receptor and a region that is
sensitive to an endogenous stimulus, as well as for
functionalization with a MRI probe. As batch pep-
tide synthesis is time-consuming, its transfer to a
continuous flow process would help to reduce to-
tal synthesis time and simplify handling [17]. A
structural characterization and purity of synthesized
crude peptides is important for their further use as
building blocks for self-assembly. Although it is gen-
erally carried out using conventional methods such
as Nuclear Magnetic Resonance (NMR) and Mass
Spectrometry (MS), these methods are not sufficient
for the analysis of peptide mixtures.

In this study, we established a strategy to develop
these new self-assembled amphiphilic peptide build-
ing blocks by combining areas of expertise in synthe-
sis, analytical methods, physicochemical characteri-
zations and MRI studies. The design of the peptide
sequences, the optimization of their synthesis, and
the deep mechanistic understanding and optimiza-
tion of their self-assembly process, were facilitated
by various methods, notably CE-MS and MRI. This
deep characterization and understanding of the self-
assembly mechanisms lays the groundwork for de-
velopment of novel and efficient theranostic agents,
and may limit animal testing.

## 2. Strategy for the design of amphiphilic peptide building blocks for nanotheranostic applications

As a starting point, the peptide sequence VVVVVKKGRGDS (P1), described by Liang et al. was chosen [18]. This amphiphilic sequence consists of a hydrophobic tail with six valines (V = Val), which can form hydrophobic interactions and promote peptide self-assembly. The sequence also contains an RGD (R = Arg; G = Gly; D = Asp) motif for targeting αvβ3 integrins, overexpressed at the surface of cancer cells. After self-assembly of the peptide, these RGDs are exposed at the nanostructure surface and available to interact specifically with these receptors and promote internalization of the nanoobject into cancer cells. The presence of two lysines (K = Lys) confers a pH-dependent character to the sequence, so that at pH 5, the ratio of protonated lysine to deprotonated lysine is 100 times greater than at pH 7, preventing self-assembly at acidic pH due to

electrostatic repulsion. In tumor tissue, the environ-
ment is slightly acidic, with a pH close to 6.8, but
decreases further in intracellular endosomes where
the pH is 4.5 [19]. A pH-dependent self-assembly is
then conducive for the triggered release of antitumor
drugs in tumors, by decrease in the pH (Figure 1).

To advance the design of a nanotheranostic agent,
an imaging probe is functionalized onto the pep-
tide sequence. The peptide P1 provides various
amine and carboxylic groups, located on the se-
quence. The functionalization of the amines would
lead to insertion of the probe inside the nanostruc-
ture, thus modifying the self-assembly process and
the probe properties. On the other hand, the func-
tionalization of the terminal carboxylic acid or the
side chain of aspartic acid (D = Asp) through amide
bond formation, could lead to possible side reac-
tions such as peptide polycondensation. Temporary
protection of these groups could be performed, but
is a multi-step functionalization process. There-
fore, a new amphiphilic peptide sequence was de-
signed by incorporating a cysteine (C = Cys) into
P1, introducing a thiol group positioned in the hy-
drophilic head to produce P2. This modification
allows for easy participation in a click chemical re-
action. As the aim is to develop MRI contrast agents,
a complexation with [(2-(4,7,10-tris(carboxymethyl)-
1,4,7,10-tetraazacyclododecan-1-yl) pentanedioic
acid)] maleimide (DOTAGA-maleimide) was ex-
plored by a thiol-maleimide conjugation, followed
by a gadolinium complexation step, as DOTAGA is a
classical complexing agent for gadolinium.

The development of this new optimized se-
quence VVVVVKKGRGDCS (P2) offers the follow-
ing advantages: (1) a biocompatible and biodegrad-
able sequence, purely composed of natural amino
acids; (2) its potential self-assembly in an aqueous
medium, allowing encapsulation of hydrophobic
drugs; (3) the presence of the RGD motif specifically
targeting αvβ3 integrin receptors, overexpressed at
the surface of cancer cells, allowing targeted drug
delivery; (4) the pH dependence of self-assembly
leading to disassembly of the nanoobject at pH less
than 5, allowing drug release triggered by a pH de-
crease in tumor microenvironments. These charac-
teristics enable peptide self-assembly to constitute
an intelligent nanovector for targeted and controlled
delivery of anticancer drugs. To complete the prop-
erties for theranostic applications, the Gd(DOTAGA)
<figure><img src="image_6.png" /><figcaption>**Figure 1.** Amphiphilic peptide sequence VVVVVVKGRGDS (P1), presenting a reversible pH-sensitive self-assembly and properties for the targeted release of anti-cancer molecules into tumor cells. Adapted from Ref. [18].</figcaption></figure>

modified peptide sequence should preserve the self-assembling properties while providing imaging properties to the nanoobject, allowing it to be monitored in vivo.

Thus, in a first step, the synthesis process was developed by solid-phase peptide synthesis, using a continuous flow process. The synthesis products were first analyzed using classical characterization methods, NMR and MS. As they are time-consuming and present limitations for complex mixtures, a separation step prior to detection was evidenced as mandatory. An electrokinetic method coupled to mass spectrometry via an ionization-desorption interface by electro nebulization (CE-ESI-MS) was simultaneously developed to quickly assess the structure and purity of synthesized crude peptides, aiding in the optimization of peptide synthesis. Indeed, CE-ESI-MS is a robust analytical method combining the resolving power of capillary electrophoresis (CE) and the sensitivity of MS, which allows a more detailed characterization of synthetic peptides [20]. Further functionalization by click chemistry with a Gd(DOTAGA) was then developed to generate an MRI probe. CE-ESI-MS was also used to monitor the progress of the reaction and study the

continuous stability of the conjugated products. Finally, an in-depth study of the self-assembly process of all the synthesized peptide building blocks was carried out using several complementary physicochemical characterization methods, such as Dynamic Light Scattering (DLS), Transmission Electron Microscopy (TEM), Circular Dichroism (CD), zetametry, Taylor Dispersion Analysis (TDA) and CE-UV. Co-assemblies of functionalized and non-functionalized peptides were then studied to better understand the formulation process, and their magnetic relaxivities were measured by MRI methods. The deep physicochemical characterization of self-assembled or co-assembled nanoobjects are important in predicting their pharmacokinetics.

**3. Efficient synthesis of peptide building blocks by continuous flow guided by electrophoretic separation coupled to mass spectrometry detection**

The development of nanovectors based on self-assembling peptides relies first and foremost on the design and the synthesis of the peptide building blocks. Therefore, a versatile synthesis process was
developed, that could be optimized by physicochemical characterization of the reaction products using CE-ESI-MS.

The development and large-scale production of therapeutic peptides by Solid-Phase Peptide Synthesis (SPPS) is the method of choice for peptide synthesis. As a result, due to the continuous need to develop new reagents, resins, linkers, protected amino acids, etc., there is now a wide choice of commercial products at relatively affordable costs to synthesize almost any type of peptides. Similarly, at laboratory scale, specific reactors have been developed for manual SPPS (volume greater than 10 mL), called “batch” synthesis, as well as microwave-assisted synthesizers for automated synthesis adapted for SPPS with the 9-fluorenylmethoxycarbonyl (Fmoc) strategy [21]. Microwave-assisted synthesis remains the method of choice for the construction of long or difficult sequences. Nevertheless, over the last decade, there has been renewed interest in continuous flow peptide synthesis, which offers significant advantages over the above-mentioned processes [17]. Continuous flow SPPS is performed by the loading of a resin containing grafting sites (alcohol functions in this study) into a fixed-bed reactor, through which the reagents and solvents are percolated [21]. The immobilization of the resin in the reactor permits: (1) reducing the required amount of solvent and reactant amounts and the total synthesis time [22]; (2) generating an efficient and simplified removal of excess reagents and byproducts through rinsing with a solvent; and (3) favoring rapid coupling kinetics due to continuous reactant excess on a new grafting site avoiding dilution effects [17]. In addition, a major advantage of flow SPPS is the ability to integrate several online modules for versatile control of some experimental parameters or follow-up of the reactions. For example, online coupling to UV-Vis absorbance detection allowed monitoring the progress of coupling and deprotection reactions in real time by the absorbance of the products [23], without interrupting the synthesis. A complementary online measurement of internal pressure variation [24] identified changes in resin volume, due to its swelling during the coupling, or its contraction during Fmoc deprotection, or peptide aggregation on the resin. In another example, a high temperature (90 °C) loop for reagents activation was connected at the inlet side of the reactor [25–27].

In this context, we aimed at developing a rapid and simple to implement process to provide versatility in sequence synthesis. A continuous flow SPPS protocol was optimized to obtain the desired peptide sequences for further self-assembly of the peptide building blocks. Briefly, flow synthesis began with resin swelling, followed by *n* cycles of peptide coupling, *n* being the number of amino acids in the desired sequence, and a final rinse to contract the resin and remove it from the reactor. The resin was then transferred to a flask for peptide cleavage, side-chain deprotection, and peptide precipitation (Figure 2).

The development of this new SPPS in flow reactors was first inspired by previous studies in our laboratory (results not shown) and different technological difficulties were first resolved. The DMF flow rate for resin introduction was optimized at 0.8 mL·min⁻¹ for 30 min, which was a compromise between rapid column packing and possible heterogeneities in the swollen resin at higher flow rate, impacting the synthesis efficiency. Then, the volume of the resin during the synthesis increased due to the elongation of the peptide on the resin, as evidenced by a higher back pressure. Therefore, the system was optimized with a fixed-end column, instead of a piston; once the resin had swollen, it was manually packed with sand to hold it in place, so that the resin could swell freely during the synthesis. Finally, in conventional SPPS protocols, a final rinsing of the resin with CH₂Cl₂ is used to remove DMF, which may interfere with the final peptide cleavage step. However, the resin (Chem-Matrix resin) used in this project swelled even more in CH₂Cl₂ than in DMF [28], leading to high back pressure. When optimizing our protocol, CH₂Cl₂ was replaced by Et₂O to rinse the resin directly, as well as to contract and remove the resin from the column. To the best of our knowledge, except for an application note, belonging to the Vapourtec® company, and one study on the development of SPPS on a microfluidic chip [29], the peptide cleavage step was rarely performed in continuous flow. Typically, the resin is removed from the reactor and any residual solvent is evaporated under vacuum before cleavage. It is also worth mentioning that all resins in the market swell almost twice as much in TFA (which is used for the deprotection step) as in organic solvents conventionally used in SPPS. In a flow reactor, this rapid and significant swelling is likely to create strong back
<figure><img src="image_7.png" /><figcaption>**Figure 2.** Chemical reactions involved in peptide synthesis and workflow.</figcaption></figure>

pressures. We therefore developed this final cleavage step in batch.

The product of this first synthesis (P1–F1) was analyzed by NMR (Figure 3A), and compared to a reference product, indicating that the sequence is missing amino acids, most likely serine (S = Ser) and aspartic acid (D = Asp). These are the first two amino acids added during SPPS, suggesting that the bonding to the resin was not as effective as expected. As structural analysis of the product by NMR alone was insufficient to establish the peptide composition, HRMS and MS/MS analyses were also carried out, revealing a mixture of peptide sequences in the product (Figure 3B and C). In particular, three truncated sequences were identified from ions detected in positive ionization mode: VVVVVKKGR (calc. 1081.7, found 541.9 (Z = 2), 361.6 (Z = 3), 271.4 (Z = 4)), VVVVVKKGRD (calc. 1196.8, found 599.4 (Z = 2), 399.9 (Z = 3), 300.2 (Z = 4)) and VVVVVKKGRDS (calc. 1283.8, found 642.9 (Z = 2), 428.9 (Z = 3), 322.0 (Z = 4)).

Therefore, the raw product obtained in this first step did not contain the complete sequence and the first amino acids added during the synthesis were

missing. Moreover, although structural analysis of the product by NMR and MS can identify the composition of the different peptide sequences, these classical characterization methods have their limitations. Indeed, the analysis of peptide NMR and HRMS spectra is particularly complex and time-consuming, especially for mixtures of sequences.

To guide optimization of P1 synthesis, the use of faster and more resolutive analytical methods that required little or no sample preparation was essential. The sensitivity of MS makes it the detection method of choice in proteomic analysis, but it has to be coupled with a separative method to easily characterize peptide sequence mixtures. Reversed-phase HPLC (RP-HPLC) is classically employed for either peptide characterization or purification. However, some peptide mixtures of similar polarities may co-elute, highlighting the need for complementary analytical methods to assess synthetic peptide purity. Compared to HPLC, CE offers higher separation selectivity and efficiency, lower reagent and sample consumption, lower waste generation, and shorter analysis time. Furthermore, CE selectivity is based on differential electrophoretic mobilities, according
<figure><img src="image_8.png" /><figcaption>**Figure 3.** (A) 2D COSY NMR spectrum of P1–F1 (blue) overlaid with a reference P1 peptide (red). (B) ESI-HRMS and (C) MS/MS spectra of P1–F1.</figcaption></figure>

to the charge over size ratio of the compounds, in-
stead of differential interactions with a stationary
phase for HPLC. Coupled to the high sensitivity of
the MS detection with ESI interface, a soft ioniza-
tion mode, molecular masses and structural infor-
mation can be obtained [30]. In 1994, CE coupled
to MS by an electrospray ionization–desorption in-
terface (CE-ESI-MS) was developed for the analysis
of a synthetic short fragment of heregulin-β pep-
tide (1959.8 Da) [31]. While HPLC evidenced a sin-
gle peak in the chromatogram, CE-ESI-MS proved
the presence of two peaks, corresponding to the
expected peptide along with a dehydration prod-
uct. An efficient separation of a mixture of synthetic
gonadotropin releasing hormone (GnRH) decapep-
tides, which could not be resolved by HPLC, was also
successfully performed by CE-ESI-MS [32]. A CE-ESI-
MS qualitative identification of short peptide por-
tions of the extracellular domain of a glycoprotein
growth factor was performed in the mg·mL⁻¹ con-
centration range [33]. Other developments with CE
or CE-MS, either offline or inline, are described for
applications in proteomics [34], peptide therapeu-
tics [35] or design of cyclic peptides [36] among oth-
ers, but to our knowledge, no other work has been
reported so far on CE-ESI-MS for purity assessment
and sequence check of synthetic peptides at low con-
centration level (0.1 mg·mL⁻¹).

Therefore, a CE-ESI-MS characterization method
was developed in parallel to optimize the synthesis
and obtain the complete sequence with better yield
and purity [37]. This synergistic contribution may
overcome the deficiencies evidenced previously on
the peptide synthesis. The analysis of the products
of P1–F1 synthesis evidenced six main peptide se-
quences missing the first amino acids that should be
anchored to the resin (Figure 4). These initial re-
sults highlight the powerful efficiency of CE sepa-
ration coupled to the efficient structure determina-
tion of MS, as CE-ESI-MS proved the presence of six
truncated sequences, whereas previous results with
HRMS and MS/MS only determined three of them.

Optimization of the synthetic workflow was then
performed by CE-ESI-MS characterization. Figure 5
illustrates the three main peptide sequences that
were identified at each step of this optimization. As
the first amino acids that should be anchored on
the resin were missing, a new protocol was tested
including a longer residence time by decreasing the
flow rate (from 2.5 to 1 mL·min⁻¹) (P1–F2). How-
ever, the last two or three amino acids were still
missing. For each amino acid, two successive cou-
pling solutions were then percolated through the
reactor (“double coupling” of the amino acids). Ac-
cording to CE-ESI-MS characterization of P1–F3,
an improvement of the synthesis occurred, as only
<figure><img src="image_9.png" /><figcaption>**Figure 4.** (A) CE-UV electropherogram of P1–F1 in 20 mM ammonium formate BGE (pH 3.7). (B) Extracted-ion signals from the total ion CE-ESI-MS electropherogram at specific *m/z* values summarized in (C). (C) Identification of the different sequences in P1–F1, with their corresponding missing amino acids and their relative abundance in the sample.</figcaption></figure>

the first amino acid (S = Ser) was still missing in one sequence. This could be due to a difference of reactivity between the resin's linker and the amino acids. In one case, during anchoring to the resin, the carboxylic acid of the amino acid reacted with an alcohol function on the linker. In the other case, during the coupling between two amino acids, the carboxylic acid reacted with an amine, which is more nucleophilic than an alcohol. To make the alcohol on the linker more nucleophilic, it must be deprotonated with a strong base to form the alkoxide. In this first protocol, N,N-DiIsoPropylEthylAmine (DIPEA) was used combined with (dimethylamino)-N,N-diméthyl(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)méthaniminium hexafluorophosphate (HATU)

to couple the first amino acid with the resin. As they did not seem to be strong enough to deprotonate the alcohol function, they were replaced by N,N'-DiIsopropylCarbodiimide, catalyzed by 4-DiMethylAminoPyridine (DIC/DMAP), a combination commonly used for grafting onto such resin [38,39]. However, HATU/DIPEA was retained for the other peptide couplings, as the DIC/DMAP has disadvantages such as lower yields, side reactions and racemization of the amino acid [40]. Thus, the synthesis protocol was modified to differentiate the resin grafting step from the peptide coupling one. The attachment of serine (S = Ser) to the resin was carried out as a double coupling, using the new DIC/DMAP reagents. The
<figure><img src="image_10.png" /><figcaption>**Figure 5.** Summary of the various synthesis optimizations, guided by CE-ESI-MS characterization of the crude P1 products synthesized by continuous flow. For each synthesis, the three principal sequences were identified and their percentage are presented.</figcaption></figure>

other peptide couplings were carried out as single couplings, with HATU/DIPEA. This choice was made to reduce the quantity of reagents and to evaluate the efficiency of the new binding conditions of the first amino acid on the resin.

This protocol (P1–F4) allowed to obtain the expected peptide sequence with 72% purity. The coexistence of truncated sequences could be explained by the fact that, after the 1st amino acid was anchored on the resin, the remaining functions on the surface of the resin are still accessible for the subsequent introduced amino acids. Blocking these free functions would potentially prevent the formation of these truncated sequences. Therefore, a final synthesis (P1–F5) was optimized by adding a blocking step (“capping” of the resin) for unreacted grafting sites on the resin with acetic anhydride (Ac₂O) after the anchoring of the first amino acid.

Again, CE-ESI-MS analysis of the products generated by this new protocol showed an increase of the purity of the expected peptide sequence up to 82%. This time, residual remaining truncated sequences were mostly related to missing amino acids in the end of the sequence, due to a non-quantitative peptide bond formation with the hydrophobic valines. This result validates the interest of adding a capping step

to the protocol.

Thanks to the synergistic contribution of synthesis and analytical developments, the peptide synthesis in continuous flow could be improved in several ways. The modulation of the flow allowed improving the efficiency while preserving a reduced time for synthesis; the coupling efficiency could be further enhanced by identifying the limiting step (anchoring to the resin) for which “double coupling” was implemented while changing the reactants. Finally, capping the resin, after the first amino acid has been grafted, allowed optimization verified by CE-ESI-MS characterization, enabling a peptide coupling cycle to be completed in less than 30 min. The entire sequence from resin swelling to peptide precipitation could be achieved in three days. With a rudimentary SPPS system in continuous flow, a significant improvement of the time for the complete synthesis has been achieved, compared to batch synthesis, which takes several weeks. This reduced time will be particularly important when modifications to the amino acid sequence are required to study the influence of the sequence nature on self-assembly. For this, it will be necessary to rapidly synthesize a library of modified sequences. In addition, the synthesis has been optimized on a small scale (200 mg resin), but the protocol is perfectly suited for
scale up and producing peptides in larger quantities. A miniaturization of the SPPS could also be considered in the future, to transfer the current millifluidic process to the microfluidic scale, where heat and mass transfer will be improved, that would reduce the time for the complete synthesis, and enable even faster optimization of operating conditions [41]. All the main characterized sequences in the product mixture contain RGD, the αvβ3 integrin targeting motif, and at least two valines capable of generating self-assembly of the peptide by hydrophobic interaction. Therefore, their self-assembly without purification may lead to mixtures of nanostructures, which may be compatible with their future use.

## 4. Efficient peptide functionalization with a MRI contrast agent guided by electrophoretic separations coupled to mass spectrometry

Magnetic Resonance Imaging (MRI) is one of the most widely used medical imaging methods to diagnose pathologies, including cancer. It is a non-invasive method based on the magnetic relaxation of nuclear spins of protons in water molecules, enabling tissue structure to be imaged. When image contrast is insufficient to differentiate between healthy and diseased tissue, an imaging probe, often a gadolinium complex (Gd), is injected to enhance contrast by increasing the magnetic relaxivity of water molecules.

Our strategy consisted of functionalizing the peptide sequence with a gadolinium complex, as Gd-Based Contrast Agents (GBCA) are the most used Contrast Agents (CA) in clinical MRI [42], and then formulating the self-assembly of the Gd complex functionalized peptide. Therefore, few strategic points had to be considered: the functionalization should be performed to preserve the pH-sensitive self-assembling properties, the active targeting by the RGD sequence, and the positioning of the MRI probe in the vicinity of the nanoobject surface, for an efficient MRI response.

For more than 20 years, GBCAs have been developed to bind to different ligands, such as antibodies, proteins, peptides, aptamers, polysaccharides, etc. [43]. In this context, peptides could be easily functionalized thanks to the diversity of their

functional groups (amine, carboxylic acid, thiol) allowing for many bioconjugation strategies including click chemistry, peptide coupling and other chemoselective reactions [8,44]. In the peptide sequence P1, the self-assembly process leads to internalization of the primary amines, therefore their functionalization could impede the self-assembling process when functionalized. The two available carboxylic functions, the terminal carboxylic acid and the aspartic side chain, could be functionalized by the formation of an amide bond through peptide coupling with an amine. However, a peptide polycondensation could occur between the amines and the carboxylic acids present in the sequence. To avoid side reactions, a strategy with temporary protection groups on the peptide could be developed, however complicating the synthesis of the conjugate and lowering conjugation yields [44]. As the peptide functionalization should be specific, click chemistry appears as an interesting alternative, providing fast reactions and high yields. Particularly, a thiol-maleimide bioconjugation strategy could be developed, as maleimides react, without heat or catalytic processes, specifically with thiols, forming thiosuccinimides [45,46].

For this purpose, the rational design of a peptide sequence for developing theranostic agents consisted of modifying the initial peptide sequence P1 (VVVVVKKGRGDS) by including a cysteine (C = Cys), with a thiol function, to facilitate its functionalization by a thiol-ene reaction with a chelating ligand, followed by complexation with Gd [47] (Figure 6A). This new designed sequence P2 (VVVVVKKGRGDCS) provided a cysteine positioned in the hydrophilic head, just before the terminal amino acid, therefore close to the surface of the self-assembled nanostructure and preserving the RGD sequence. The selection of the ligand was made based on an efficient and specific functionalization and a strong complexation to Gd to avoid its leakage during theranostic applications. Therefore, cyclic DOTAGA ((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl) pentanedioic acid) was selected as the complexing agent for its high complexation constant ($\log K = 24.78$) and thermodynamic stability to Gd$^{3+}$ chelator [48] (Figure 6B).

Two strategies were envisioned for this functionalization: either functionalizing the peptide sequence before self-assembly or functionalizing the peptide
<figure><img src="image_11.png" /><figcaption>**Figure 6.** (A) Molecular structure of P2 peptide, with $pK_a$ values of ionizable functions. (B) General scheme of the functionalization of P2 with DOTAGA via thiol/maleimide reaction, followed by Gd complexation, in 20 mM acetate buffer (pH 5.5). Adapted from Ref. [47].</figcaption></figure>

self-assembly. The first strategy was preferred as it would allow a better monitoring of the functionalization step and to be able to better control the number of Gd-DOTAGA on the final nanother-anostic agent, without destabilizing the preformed supramolecular nanostructures. Indeed, to avoid Gd-DOTAGA crowding of RGD motifs on the surface of the self-assembled nanostructure, co-assemblies between non-functionalized and functionalized peptides were explored (Figure 7).

Acidic conditions were then necessary for the whole synthesis process to preserve the peptide in its monomeric form. Furthermore, enriched by our experience in efficient optimization of peptide synthesis followed by an electrokinetic method, a synergistic contribution of a new CE-ESI-MS development to follow the functionalization step and purification check was undergone.

The functionalization consisted of a two steps procedure: (1) mixing DOTAGA-maleimide (DOTAGA-mal) with the peptide solution (P2), dissolving in 20 mM acetate buffer (pH 5.5), at different molar ratios (0.1 equiv, 0.15 equiv, 0.2 equiv or 1 equiv), and stirring at room temperature for 2 h; (2) followed

by addition of Gd (10 mM GdCl₃ solution) to the previous solution, 4.5 equiv compared to the amount of DOTAGA-mal added previously, and stirring overnight at room temperature. The resulting solution was, in few cases, dialyzed with 20 mM acetate buffer (pH 5.5) with a membrane of 0.1–0.5 kDa cut-off, to eliminate the excess of Gd. This procedure was optimized at each step thanks to CE with dual UV and MS detection [47].

In a first step, the DOTAGA-maleimide (DOTAGA-mal) functionalization on the thiol present in the peptide was performed in a 1:1 ratio (DOTAGA-mal/thio-peptide). The electrophoretic mobilities of the resulting crude product (P2-DOTAGA) without dialysis, along with the starting materials (P2 and DOTAGA-mal) were determined by CE-UV (Figure 8A). They were coherent with the global charge of each species in the background electrolyte (20 mM ammonium acetate, pH 5.5). An electrophoretic mobility around $2 \times 10^{-5} \text{ cm}^2 \cdot \text{V}^{-1} \cdot \text{s}^{-1}$ was determined for P2 (black line) in accordance with a +2 charged species; around $-30 \times 10^{-5} \text{ cm}^2 \cdot \text{V}^{-1} \cdot \text{s}^{-1}$ for DOTAGA-mal (blue line), that is expected to be twice negatively charged [49,50]. The crude mixture pre-
<figure><img src="image_12.png" /><figcaption>**Figure 7.** Scheme of the co-assembly structure from P2 and P2-Gd(DOTAGA). Adapted from Ref. [47].</figcaption></figure>

sented an intense peak at −2.5 × 10⁻⁵ cm²·V⁻¹·s⁻¹, ex-
pected to be the one of P2-DOTAGA conjugate along
with a small peak at around −30 × 10⁻⁵ cm²·V⁻¹·s⁻¹
corresponding to excess DOTAGA-mal. The attribu-
tion of the peaks was confirmed by CE-ESI-MS (Fig-
ure 8B and C) on the crude mixture, thanks to the
extracted ion electropherograms from the total ionic
current (black line) of *m/z* = 682, 723 and 599, cor-
responding to specific ions of P2-DOTAGA, P2 and
DOTAGA-mal, respectively. The large peak corre-
sponds to P2-DOTAGA (full red line), confirming the
success of the functionalization reaction in just 2 h,
with the presence of P2 (full black line) and DOTAGA-
mal (full blue line) being in little abundance, 4% and
2% respectively.

As our aim was to formulate direct co-assemblies
between non-functionalized and functionalized
peptides, the synthetic procedure was then per-
formed with different molar ratios (0.1 equiv, 0.15
equiv or 0.2 equiv) between DOTAGA-mal and P2.
This permitted obtaining mixtures of P2 and P2-
DOTAGA conjugates, with relative amounts of func-
tionalized peptide of 10%, 15% and 20%, labelled
P2-DOTAGA10, P2-DOTAGA15 and P2-DOTAGA20,
respectively, that could then be directly formulated,
without a purification step, therefore with a gain in
time. The rate of functionalization was monitored
by CE-ESI-MS on the crude mixture without dial-
ysis (Figure 9). For all three P2-DOTAGA samples,
the UV signals evidenced the peak of P2-DOTAGA
at around neutral mobility and the one of P2 at
15 × 10⁻⁵ cm²·V⁻¹·s⁻¹, while no peak of DOTAGA-
mal (expected at −30 × 10⁻⁵ cm²·V⁻¹·s⁻¹) was seen,

confirming a 100% grafting rate of DOTAGA what-
ever the initial P2/DOTAGA-maleimide ratio. Exper-
imental functionalization rates of the mixtures were
then calculated from each peak area, taking into
consideration any dilution effect, leading to 11%,
19% and 22% for P2-DOTAGA10, P2-DOTAGA15 and
P2-DOTAGA20, respectively, which are consistent
with the theoretical ones.

Gd complexation was then performed on
these mixtures, leading to P2-Gd(DOTAGA)10, P2-
Gd(DOTAGA)15 and P2-Gd(DOTAGA)20 (Figure 10A),
and the products were characterized by CE-ESI-MS.
Two main peaks were shown for the three mix-
tures on the total ion signal, identified as P2 for the
peak at 14 min (m/z = 723 and 482, [M+2H]²⁺ and
[M+3H]³⁺, respectively) and as P2-Gd(DOTAGA)
for the one at 15 min (m/z = 733, [M+3H]³⁺), ac-
cording to the single ion signals (Figure 10B for
Gd(DOTAGA)10, as an example). No peak of P2-
DOTAGA (m/z = 695, [M+H+Na+NH₄]³⁺) was evi-
denced, proving the efficiency of the complexation
step and confirming that all the DOTAGA grafted on
P2 are under Gd(DOTAGA) complex form. This two-
step functionalization strategy afforded mixtures of
P2 and P2-Gd(DOTAGA) with a very simple proce-
dure without purification, in a short time (14 h), and
that can directly be used for future co-assemblies
in the formulation of nanovectors. Figure 10B rep-
resents the CE-ESI-MS for Gd(DOTAGA)10, as an
example.

The stability of P2-Gd(DOTAGA)10, P2-
Gd(DOTAGA)15 and P2-Gd(DOTAGA)20 dispersions
was assessed by CE-ESI-MS, in the same condi-
<figure><img src="image_13.png" /><figcaption>**Figure 8.** (A) CE-UV electropherograms of DOTAGA-maleimide (DOTAGA-mal) (blue), P2 (black) and the crude functionalization product (red), in 20 mM ammonium formate buffer (pH 5.5). (B) CE-ESI-MS electropherogram of the reaction product. Total ion signal (m/z 100–1200, black line) and extracted ion signals specific of P2-DOTAGA (red), of P2 (black) and of DOTAGA-maleimide (blue). (C) Extracted mass spectrum from the total ion electropherogram (black line in (B)) of the reaction product under the peak at 15.5 min. Adapted from Ref. [47].</figcaption></figure>

tions as previously after 1 month storage at 4 °C. On the one hand, the free thiol moieties on the non-functionalized peptide are expected to form disulfide bonds leading to dimers. On the other hand, Gd decomplexation is unlikely due to the high complexation constant (log K = 24.78) [48], but hydrolysis of the thiosuccinimide moiety could occur on the functionalized peptide [51]. CE-ESI-MS characterization confirmed that non-functionalized peptide monomers had begun to form disulfide bonds after 1 month in solution. However, the higher the functionalized peptide ratio is in the mixture, the less this aging process is observed. No thiosuccinimide hydrolysis, Gd decomplexation or other degradation of the peptide sequence

was evidenced. Bearing in mind the further use of these peptide products as structural building blocks to form self-assembled nanostructures, it may be worthwhile to study the impact of the formation of peptide dimer, when stored, on the self-assembly. Furthermore, optimized storage procedures could be studied to limit sample transformation through time.

In summary, a Gd(DOTAGA) complex was functionalized on P2 (VVVVVKKGRGDCS) by the addition of thiol function to the maleimide. A DOTAGA was first bound to the peptide, followed by complexation of the Gd³⁺ ion by the ligand. Again, CE-ESI-MS appeared to be an appropriate analytical method for functionalization and aging studies of peptide conjugates.
<figure><img src="image_14.png" /><figcaption>**Figure 9.** (A) Reaction scheme of the functionalization of P2 with different amounts (0.1, 0.15 and 0.2 equiv) of DOTAGA-maleimide in 20 mM acetate buffer (pH 5.5), to form mixtures of P2 and 10, 15 and 20% of P2-DOTAGA, called P2-DOTAGA10, P2-DOTAGA15 and P2-DOTAGA20, respectively. (B) CE-UV electropherograms of P2 and mixtures P2-DOTAGA10, P2-DOTAGA15 and P2-DOTAGA20 in 20 mM acetate buffer (pH = 5.5). Adapted from Ref. [47].</figcaption></figure>

gates based on simplicity, rapidity, low sample consumption and direct analysis without requirement for sample preparation.

**5. Formulation and understanding of peptide self-assembly guided by a combination of complementary analytical and physical methods**

Peptide self-assemblies are essentially based on weak interactions [52], the combination of which leads to

the formation of well-organized and stable nanos- tructures. These structures can be designed to change the shape in response to a stimulus, such as a variation of the pH, enzymatic activity, high ROS concentration or a change in temperature [53], which is of particular interest for controlling the drug deliv- ery, where we seek to trigger the release of active in- gredients at a specific site, such as a tumor.

A deep understanding of peptide self-assembly would be of great interest for both the design of new peptide sequences and the optimization of the for-
<figure><img src="image_15.png" /><figcaption>**Figure 10.** (A) Reaction scheme of the complexation of Gd by P2-DOTAGA, to form mixtures of P2 and 10, 15 and 20% of P2-Gd(DOTAGA) in 20 mM acetate buffer (pH 5.5). (B) CE-ESI-MS electropherogram of mixture P2-Gd(DOTAGA)10, with the total ion signal (black, *m/z* 400–1150) and single ion signals at *m/z* values specific of P2 (red), P2-DOTAGA (green) and P2-Gd(DOTAGA) (blue). The left and the right axes correspond to the abundance for the total ion signal and the single ion signals, respectively. Adapted from Ref. [47].</figcaption></figure>

mulation conditions [54]. Therefore, several com-
plementary methods were used for characterizing
the self-assembly of the previously synthesized pep-
tides: pH measurement, Dynamic Light Scattering
(DLS), Transmission Electron Microscopy (TEM),
Circular Dichroism (CD), CE-UV and Taylor Disper-
sion Analysis (TDA) in capillary format. The strat-
egy was to test the peptides P1 and P2, present-
ing no functionalization, along with the function-
alized peptide P2 (P2-DOTAGA), and the mixtures
of P2 and P2-Gd(DOTAGA) (P2-Gd(DOTAGA)10, P2-
Gd(DOTAGA)15 and P2-Gd(DOTAGA)20), to increase
complexity in nanostructures and gain insights into
the involved mechanisms.

A first attempt to reach P1 self-assembling was re-
alized according to Liang et al. [18] by dissolving P1 at
0.05 or 0.5 g·L⁻¹ in water. However, no self-assembly
was observed, probably due to the respective pHs
of 4.5 and 3.5 of the sample solution. An increase
in pH was then performed by progressive addition

of small volumes (20 µL) of 1 M NaOH, which led to
precipitation when a pH value around 6 was reached.
A second attempt consisted of a dialysis-assisted
formulation, inspired by Liang et al. [18] was again
unsuccessful. Therefore, a new P1 self-assembly
pathway using rapid addition of NaOH was devel-
oped, with successive volumes of less than 20 µL
of 1 M NaOH solution to avoid dilution effect,
and a stable colloidal solution was obtained when
the pH reached a value of 11. Knowing that the
“Critical Micellar Concentration” was estimated at
0.02 g·L⁻¹ [18], three P1 concentrations were tested
(0.5, 1 and 2 g·L⁻¹) and DLS measurements evi-
denced nanostructures with average diameters of
50 nm and a polydispersity index (PDI) of 0.2 or be-
low, indicating no correlation between self-assembly
size and initial P1 concentration, in the 0.5 to 2 g·L⁻¹
range (see Figure 11A for 1 g·L⁻¹). Aging studies with
a period of 19 days proved a good colloidal stability
for P1 solutions at 0.5 and 1 g·L⁻¹, with a preser-
vation of their initial size and dispersion medium pH, whereas the P1 solution at 2 g·L⁻¹ underwent an increase in nanostructure hydrodynamic diameter up to 110 nm along with a decrease in pH to 10.3 after 14 days, leading to peptide precipitation. Decrease in pH could be explained by peptide amphoteric properties that may alter the pH of the dispersion medium at high concentrations with slow kinetics. Following these observations, self-assembly studies were continued at 1 g·L⁻¹ where the sample appeared to be the most stable in terms of pH and nanostructure hydrodynamic size. TEM images were then performed by deposition of the sample on a copper grid coated with a carbon/Formvar film followed by deposition of an aqueous solution of uranyl acetate (2%) to color the sample and improve the image contrast, and finally air-drying of the grid. Images demonstrated short nanorods with lengths of 46.1 ± 12.2 nm and diameters of 9.2 ± 2.7 nm. To assess grid preparation without impairment of the self-assembly, cryo-TEM images were then performed, confirming the nanorods with the same dimensions (Figure 11B). The difference in size from DLS to TEM is expected and coherent. DLS measures the apparent hydrodynamic diameter of an equivalent spherical particle (as the detection angle in this study was of 173° with backscatter). Back scattering measured in DLS is sensitive to the largest dimension of non-symmetrical nanoobjects. TEM measures actual solid dimensions, associated with morphology.

To elucidate the interactions involved under these conditions in the nanostructuration of P1, circular dichroism (CD) measurements were carried out. For this purpose, P1 was either dissolved in water (pH = 3), in water with the addition of 2 equiv of NaOH (pH = 7) or 10 equiv of NaOH (pH = 11). At pH 3 and 7, a random coil conformation was evidenced, whereas a β-sheet structuration was observed for the solution at pH 11 (Figure 11C). It is very likely that the β-sheets are formed by inter-peptide hydrogen bonds at the polyvaline level, valine being an amino acid with a high propensity to form β-sheets [55]. The amine on the lysine side chain (pKₐ 10.5) should be protonated at pH 3 or 7, leading to electrostatic repulsion that impedes β-sheet formations. Their deprotonation at pH 11 should eliminate this repulsion, allowing for self-assembling. In addition, the zeta potential of self-assembled P1 structures at pH 11 was measured, indicating a strong negative surface charge, with a

zeta potential value of -38±9 mV. This result suggests that P1 self-assembles into a structure that exposes to the solvent negatively charged functions, i.e. the carboxylates of aspartic acid (D = Asp) and serine terminal acid (S = Ser), from the hydrophilic head of the sequence.

CE-UV experiments were carried out for in-depth characterization of P1 (1 g·L⁻¹), self-assembly (Figure 11D). In a 10 mM sodium phosphate separation buffer (pH = 11), P1 was separated, either dissolved in water (pH = 3) in its monomer form; or after addition of NaOH (10 equiv) to the previous solution, in its nanostructured form (pH = 11).

The electrophoretic profiles are similar, corresponding to a negatively charged species, with an electrophoretic mobility of -30 × 10⁻⁵ cm²·V⁻¹·s⁻¹, consistent with the one determined by zetametry at pH 11 (-30 ± 7 × 10⁻⁵ cm²·V⁻¹·s⁻¹). Furthermore, these CE-UV characterizations reveal a fast self-assembly kinetics, compared to the time of separation. Indeed, P1, initially solubilized at pH 3, self-assembles during the separation in the capillary, due to the pH value (pH = 11) of the separation medium, this pH value being previously proved as efficient for peptide self-assembly.

All these combined physicochemical characterizations demonstrate the self-assembly of P1 at pH 11 into elongated, nanorod-like micelles.

The cylindrical morphology could be explained by the β-sheet interactions between the valines, leading to a stable nanostructure (Figure 12). Considering that an amino acid measures 3.4 Å [56], P1 would measure around 4 nm. This order of magnitude is consistent with a rod structure showing an estimated diameter of 9.2 ± 2.7 nm in TEM. This new structuration mechanism identified here for P1 is coherent with what was described in the literature with other peptide sequences. Wang et al. described the self-assembly of A9K into nanorods at pH 6, with lengths less than 100 nm [57]. The authors stated that the structuration could be due to β-sheets formation. However, they did not study the influence of pH on self-assembly of A9K, contrary to what has been studied in this work.

As indicated previously, another peptide sequence (P2) was designed to provide an additional cysteine (C = Cys) compared to P1, to facilitate the peptide functionalization with an MRI probe in view to combine smart drug delivery and imaging proper-
<figure><img src="image_16.png" /><figcaption>**Figure 11.** (A) Size distribution of self-assembled P1 (1 g·L⁻¹) at pH 11 obtained by DLS, in percentage of number of particles. (B) TEM and cryo-TEM images of self-assembled P1 at pH 11. (C) Circular dichroism spectra of P1 dissolved at pH 3, pH 7 and pH 11. (D) CE-UV electropherograms of P1 dissolved at pH 3 (blue) and pH 11 (red), analyzed in 10 mM sodium phosphate buffer (pH 11). Adapted from Ref. [54].</figcaption></figure>

<figure><img src="image_17.png" /><figcaption>**Figure 12.** Proposed nanostructuring of P1 at pH ≥ 11, as a cylindrical nanorod stabilized by inter-peptide hydrogen bonds between polyvalines. Adapted from Ref. [54].</figcaption></figure>

ties. Therefore, the self-assembly characterization of these new peptide sequences was carried out at a 1 g·L⁻¹, in the same way as for P1. The self-assembly of P2 or P2-DOTAGA was studied in a first step, followed by the co-assembly study of a mixture of P2

and P2-Gd(DOTAGA) at different ratios. All the samples were formulated at pH 11, according to the previously described protocol for P1 and characterized by combined methods.

Regarding P2, DLS measurements showed the
preservation of self-assembling properties, which is
consistent with the fact that the presence of the cysteine (in the hydrophilic head of the peptide) must
not interfere with the formation of β-sheets due to
the polyvalines (Table 1). A monodispersed distribution was determined at a hydrodynamic diameter
of 36 ± 6 nm (PDI = 0.16). Furthermore, TEM and
cryo-TEM images revealed the presence of nanorods
with a length of 27.2 ± 8.4 nm and a diameter of 7.3 ±
1.5 nm. A similar diameter and a smaller rod length
was evidenced by TEM when comparing P2 and P1
(Table 1). An insignificant modification in hydrodynamic diameter was evidenced for P2 by DLS, compared to P1. This could be explained by the presence
in P2 of the thiolate form of the cysteine at pH 11,
leading to an additional negative charge, that could
disrupt more rapidly the rod elongation than in the
case of P1. To confirm these results, the diffusion
coefficient of P2 was measured by Taylor Diffusion
Analysis (TDA) performed in a capillary, leading to a
value of 87.5 ± 1.9 × 10⁻¹¹ m²·s⁻¹ (corresponding to
a hydrodynamic diameter of 33.6 ± 0.6 nm) at pH 11,
and a value of 18.9 ± 15.7 × 10⁻¹¹ m²·s⁻¹ (corresponding to a hydrodynamic diameter of 3.40 ± 0.93 nm)
at pH 5.5 (Table 1). The hydrodynamic diameter at
pH 11 is the same as the one determined by DLS, reiterating P2 self-assembly. At pH 5.5, the hydrodynamic diameter indicates the presence of P2 in its
monomeric form and is congruent with similar data
from the literature (2.0 ± 0.2 nm measured by TDA
for oxytocin, a 1 kDa peptide) [58]. Thus, DLS, TEM,
cryo-TEM and TDA confirmed that P2 does indeed
self-assemble into nanorods at pH 11, with similar dimensions to P1. The interest of TDA for such characterizations should be highlighted, as the monomeric
form could be evidenced with TDA, whereas it was
not possible with DLS.

To design the contrast agent based on P2 self-
assembly, the latter was first functionalized with
DOTAGA. P2-DOTAGA was formulated, and analyzed
by DLS, which evidenced monodisperse nanostruc-
tures (PDI = 0.19) with a hydrodynamic diameter of
67 ± 22 nm. This proves that the self-assembly prop-
erty of P2 is well preserved even after DOTAGA func-
tionalization. Furthermore, the twice larger size of
the P2-DOTAGA nanostructure compared to P2 could
be explained by the steric hindrance generated by
DOTAGA, but this larger size is not problematic as it
remains within the desired size range (<100 nm) for

biomedical applications.

The functionalized P2-DOTAGA was then com-
plexed with Gd. Nonetheless, to avoid Gd(DOTAGA)
crowding of RGD motifs at the surface of the
self-assembled nanostructure, co-assemblies be-
tween functionalized (P2-Gd(DOTAGA)) and non-
functionalized (P2) peptides were explored, in a ratio
of 10, 15 and 20% of P2-Gd(DOTAGA) in the mixture.
The choice of co-assembly ratios was made on the
basis of the following criteria: (1) the presence of Gd
at a minimum concentration is sufficient to generate
good MRI contrast; (2) Gd(DOTAGA) is grafted close
to RGD and is likely to decrease, or even prevent it
from interacting with αvβ3 integrins. Thus, a co-
assembly composed mainly of P2 was assumed to be
rational.

For all three formulations, the hydrodynamic di-
ameters measured by DLS are identical at around
40 nm, which is congruent with the values of P2 (36 ±
6 nm) and P2-DOTAGA (67 ± 22 nm) self-assemblies.
TEM analysis also revealed nanorods with a length of
27.2±8.3 nm and a diameter of 7.3±1.5 nm (Table 2).

To delve deeper into the self-assembly character-
ization, CE-UV separation of the three formulations
was performed in a separation medium at pH 11,
with the same protocol as for P1. The sample was
analyzed after preparation either at pH 5.5 (in am-
monium acetate buffer, which corresponds to the
medium in which the functionalization was carried
out), where the sequences should remain in their
monomeric form; or at pH 11, after addition of NaOH
(40 equiv) as previously described.

For each of the three mixtures, the two solutions
show electropherograms characteristics of nega-
tively charged species, of very similar electrophoretic
mobility values (−25 × 10⁻⁵ cm⁻²·V⁻¹·s⁻¹) slightly
lower than the ones obtained for P2 (−30 ×
10⁻⁵ cm⁻²·V⁻¹·s⁻¹), which is congruent with the
difference both in size (evidenced by DLS) and
charge (cysteine functionalization reduces the sur-
face charge) of the formulations (Figure 13 for
P2-Gd(DOTAGA)20). However, the solutions pre-
pared at pH 5.5 should generate positively charged
monomers. When injected in the capillary the
sample at pH 5.5 migrates into a basic separation
medium (pH = 11), leading to negatively charged
nanostructures, due to self-assembly during the elec-
trophoretic separation process. As for P2, the self-
assembly mechanism kinetics was rapid compared
<table><caption>**Table 1.** Determination of the hydrodynamic diameter ($D_H$) by DLS and TDA, and length and diameter by TEM of the self-assembled P1 and P2</caption><thead><tr><th rowspan="2"></th><th colspan="2">DLS</th><th colspan="2">TDA</th><th colspan="2">TEM</th></tr><tr><th>D<sub>H</sub> (nm)</th><th>PDI</th><th>pH</th><th>Diffusion coefficient (10<sup>-11</sup> m<sup>2</sup>·s<sup>-1</sup>)</th><th>D<sub>H</sub> (nm)</th><th>Length (nm)</th><th>Diameter (nm)</th></tr></thead><tbody><tr><td>P1</td><td>48 ± 11</td><td>0.14</td><td></td><td></td><td></td><td>46 ± 12</td><td>9 ± 3</td></tr><tr><td rowspan="2">P2</td><td rowspan="2">36 ± 6</td><td rowspan="2">0.16</td><td>5.5</td><td>19 ± 16</td><td>3 ± 1</td><td rowspan="2">27 ± 8</td><td rowspan="2">7 ± 2</td></tr><tr><td>11</td><td>2 ± 1</td><td>34 ± 1</td></tr></tbody></table>

PDI: PolyDispersity Index. Adapted from Ref. [54].

<table><caption>**Table 2.** Determination of the hydrodynamic diameter ($D_H$) by DLS, and length and diameter by TEM of the self-assembled P2 and P2-DOTAGA and the co-assembled P2-Gd(DOTAGA)x ($x = 10, 15, 20$)</caption><thead><tr><th rowspan="2"></th><th colspan="2">DLS</th><th colspan="2">TEM</th></tr><tr><th>D<sub>H</sub> (nm)</th><th>PDI</th><th>Length (nm)</th><th>Diameter (nm)</th></tr></thead><tbody><tr><td>P2</td><td>36 ± 6</td><td>0.16</td><td>27 ± 8</td><td>7 ± 2</td></tr><tr><td>P2-DOTAGA</td><td>67 ± 22</td><td>0.19</td><td>-</td><td>-</td></tr><tr><td colspan="5">Co-assemblies</td></tr><tr><td>P2-Gd(DOTAGA)10</td><td>38 ± 12</td><td>0.24</td><td>24 ± 6</td><td>8 ± 1</td></tr><tr><td>P2-Gd(DOTAGA)15</td><td>42 ± 9</td><td>0.25</td><td>22 ± 6</td><td>7 ± 1</td></tr><tr><td>P2-Gd(DOTAGA)20</td><td>41 ± 14</td><td>0.24</td><td>22 ± 6</td><td>8 ± 1</td></tr></tbody></table>

PDI: PolyDispersity Index. Adapted from Ref. [54].

to the separation process. The presence of shoulders on the peak shapes indicates a more complex equilibrium which is coherent with a more heterogeneous sample due to random peptide co-assembly.

Therefore, these physicochemical characterizations prove the co-assembly of P2-Gd(DOTAGA) and P2, with different proportions (10, 15 and 20%) leading to self-assembled nanostructures of similar size and shape as those obtained only by self-assembly of P2. The strategy for developing these nanotheranostic agents was therefore successful in terms of nanostructuration. They could be further studied in terms of MRI properties.

## 6. Evaluation of Peptide-Gd(DOTAGA) conjugates as MRI contrast agents: a proof of concept

The principle of MRI is based on the nuclear magnetic resonance of protons in water molecules. Under the effect of a magnetic field oriented along

the z axis, the spins of the protons all align themselves along this axis, either parallel or antiparallel.

<figure><img src="image_18.png" /><figcaption>**Figure 13.** CE-UV electropherograms of P2-Gd(DOTAGA)20 dissolved at pH 5.5 (blue) or pH 11 (red), separated in 10 mM CAPS/ammonium buffer (pH 11). Adapted from Ref. [54].</figcaption></figure>
lel. Upon excitation of hydrogen nuclei of intrin-
sic water molecules and by the application of mag-
netic fields, 3D images of the proton spins are re-
constructed, and two parameters related to the re-
 laxation of the hydrogen nuclear spin are measured:
the longitudinal and transversal relaxation rates, R1
and R2, respectively, which modulate the recorded
signal. To enhance the contrast for a better visibil-
ity of the tissues structure, a contrast agent (CA) is
usually administered intravenously to the patient to
increase the contrast between diseased and healthy
tissue, and to enable a more accurate diagnosis [59].
Proton relaxation is accelerated by dipolar interac-
tions between the magnetic moments of a param-
agnetic ion of the CA and the protons of the sur-
rounding water molecules, resulting in shorter relax-
ation times T1 and T2 [60]. CAs are classified as ei-
ther T1 or T2 agents. T1 agents generate a hypersig-
nal and are generally gadolinium complexes, but can
also be manganese complexes, for example Mn(II)-
dipyridoxyl diphosphate (Mn(II)DPDP), which is the
only clinically approved Mn(II) complex [61] or iron
complexes [62]. T2 agents are compounds that gen-
erate a hyposignal and are based on iron oxide, most
often in the form of superparamagnetic iron oxide
nanoparticles (SPION) [63]. Each contrast agent is
defined by a longitudinal relaxivity r₁ and a trans-
verse relaxivity r₂, related to the longitudinal (1/T1)
and transverse (1/T2) relaxation rates, respectively.
The ratio r₂/r₁ indicates the property for the MRI
contrast agent to be T1 type (r₂/r₁ = 1, bright inten-
sity image) and to be a T2 type (r₂/r₁ > 10, darker in-
tensity image) [60].

In this study the peptide sequences P2-DOTAGA
were complexed with the Gd(III) ion, the paramag-
netic metal ion with the highest number of single
electrons (7 single electrons, S = 7/2). This prop-
erty gives Gd a very high magnetic moment, justify-
ing its use as an MRI contrast agent. As indicated
above, the paramagnetic relaxation of water protons
in the presence of a contrast agent arises from dipo-
lar interactions between the protons' nuclear spins
and the local magnetic field created by the spins of
the single electrons of the paramagnetic ion. This
magnetic field decreases with distance. There are two
contributions to paramagnetic relaxation: those of
the inner sphere and those of the outer sphere. In
the case of Gd complexes, the inner-sphere mecha-
nism is based on the interactions between the Gd³⁺

ion and water molecules involved in its first coor-
dination sphere. These water molecules exchange
energy with other molecules in the medium, prop-
agating the paramagnetic effect to the environment
around the contrast agent. As for the external sphere
mechanism, it concerns the paramagnetic effect of
Gd on the water molecules diffusing around the
complex [60].

Despite its advantages as an MRI contrast agent,
free Gd(III) in the body is acutely toxic as it interferes
with the operation at the calcium channels, which
can lead to mitochondrial dysfunction, inhibition of
neurotransmitters and muscle contraction [64]. In
order to be used safely in vivo, Gd(III) is complexed
by a polydentate organic ligand called a chelator,
which can be either linear or cyclic. These ligands are
designed to form thermodynamically stable Gd com-
plexes with very high complexation constants (Log K
of 25), to limit the release of Gd or transmetallation in
the body. As a result, complexed Gd interacts little or
not at all with tissues and is eliminated rapidly (>80%
of the injected dose is eliminated after 24 h), limiting
its accumulation in the body [65].

In 1987, gadopentetate dimeglulin Gd(DTPA)
was the first Gd complex to be approved for clinical
use and is still marketed today under the name of
Magnevist®. Since then, other Gd complexes have
been approved and have rapidly reached the mar-
ket for use in MRI: Gd(DOTA) (Dotarem®), Gd(HP-
DO3A) (Prohance®), Gd(DO3A-butrol) (Gadovist®),
Gd(DTPA-BMA) (Omniscan®), Gd(EOB-DTPA)
(Eovist®), Gd(BOPTA) (Multihance®) and Gd(MS-
325) (Ablavar®) [42]. All these complexes are based
on linear chelators such as DiethyleneTriamine-
PentaAcetic acid (DTPA) or cyclic chelators such as
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA). The cyclic ligands derived from DOTA
are preferred because they have the highest com-
plexation constants with Gd, with log K = 24.78 for
Gd(DOTA). However, the use of Gd complexes in vivo
for cancer diagnosis remains limited by the lack of
specific tumor cells targeting. Due to the low sensi-
tivity of MRI (10 µM in blood) [66], large doses must
be administered to patients, which can lead to side
effects. As with other biomedical imaging modali-
ties, the conjugation of Gd complexes with a peptide
is one of the most widely exploited strategies in re-
search for active tumor targeting. Between 2017 and
2020, more than a third of the MRI contrast agents
developed and reported in the literature were conjugated with one or more targeting peptides [67–69].

Although the active targeting of MRI peptide probes makes it possible to obtain more accurate and precise diagnoses, the size of peptide probes remains relatively small, leading to premature elimination of the product before it can fulfil its role as a contrast agent. In this context, macromolecular and supramolecular probes based on Gd complexes have been developed to improve the pharmacokinetic properties of these complexes, but also to improve the relaxivity values of existing contrast agents in order to increase contrast. One possible strategy is to increase the number of Gd per contrast agent by grafting several Gd complexes onto a peptide [70], thereby increasing the total relaxivity of the contrast agent. Another possible strategy for developing supramolecular MRI probes is the association of Gd complexes with peptides possessing self-assembly properties in nanostructures [11].

Developing MRI probes based on peptide self-assembly to increase the relaxivity of Gd complexes is very promising, but challenges still persist. Nanos-structures as probes should allow improving relaxivity by increasing the rotational correlation time through an increase in molecular mass. The correlation time also depends on the flexibility of the Gd complex linked to the macromolecular or supramolecular structure. Studies have shown that a Gd complex linked to a nanostructure by a flexible spacer retains a fast rotational correlation time, with no significant difference from a simple Gd complex in solution [71]. Thus, the design of new MRI probes is still complex, as many parameters impact the correlation time. In addition, the complexation with contrast agents should not interfere with the self-assembling process and the interaction between possible targeting ligands and their receptors.

In this project, the P2-Gd(DOTAGA) was designed so as to provide the most efficient contrast agent. First, its sequence was optimized to enable specific functionalization by introducing a thiol group on which a Gd(DOTAGA) complex was conjugated to the peptide without flexible spacer. The presence of Gd(DOTAGA) could potentially encumber the RGD targeting motifs and prevent their interactions with αvβ3 integrins. Therefore, mixtures of functionalized (P2-Gd(DOTAGA) and non-functionalized (P2) peptide at different molar ratio (i.e. 10, 15 or 20%),

were synthesized, with a view to their co-assembly. Such co-assembly would simultaneously expose the RGD motif and the Gd(DOTAGA) complex on the surface of the self-assembled nanoobject (Figure 7). The formulation of such co-assemblies was proved by the combined physicochemical characterizations, evidencing nanostructures with hydrodynamic diameters of 40 nm. Subsequently, MRI studies were performed to estimate and qualitatively compare their T1 and T2 imaging contrast and then quantitatively the relaxivity values of both monomers and co-assemblies at different ratios (P2-Gd(DOTAGA)10, P2-Gd(DOTAGA)15, P2-Gd(DOTAGA)20). The higher the relaxivity values, the more efficient the contrast agent is for MRI.

First, the relaxivity values of the P2-Gd(DOTAGA) conjugate mixtures in their monomeric form were measured, presenting well contrasting images, with a hypersignal in the T1 weighted image and a hyposignal in the T2 weighted image as expected for valuable MRI contrast agent. As a matter of comparison, Gd(DOTA) (Dotarem®), the clinical molecular Gd complex contrast agent providing the same elementary motif Gd(DOTA) used for the peptide functionalization was also analyzed (Figure 14).

P2-Gd(DOTAGA) presented $r_2/r_1$ values close to 1, similarly to Gd(DOTA) (Dotarem®). This indicates that the conjugate behaves like a T1 and T2 contrast agent. As for longitudinal relaxivities $r_1$, they increased by a factor of two, compared to Gd(DOTA). Since relaxivity is proportional to rotational correlation time ($\tau_R$), this is congruent with the larger molecular weight of P2-Gd(DOTAGA) ($M = 1443.8 \text{ g} \cdot \text{mol}^{-1}$) compared to Gd(DOTA) ($M = 558.6 \text{ g} \cdot \text{mol}^{-1}$). These relaxivity results show the enhancement of the relaxivity of the Gd complexes when conjugated to the peptide, and a $r_2/r_1$ value at around 1, in accordance with characteristic values of T1 GBCAs. These initial results were encouraging for the next step towards self-assembly of peptide-based MRI agents (Table 3).

The formulation of the co-assembled P2 and P2-Gd(DOTAGA) mixtures were then analyzed by MRI at 7 T, providing qualitative T1 and T2 weighted images showing bright intensity in concentrated samples, and darker intensity, respectively. Considering the nanostructuration of the mixture with a significant increase in molecular weight, increases in $r_1$ and $r_2$ were expected as quantitative evaluation [72].
<figure><img src="image_19.png" /><figcaption>**Figure 14.** T1- and T2-weighted MRI images of Gd(DOTA) (DOTAREM®) and P2-Gd(DOTAGA)20 at pH 5.5 and pH 11, at 7 T, 293 K. Concentrations (red) are given in mM. Adapted from Ref. [47].</figcaption></figure>

<table><caption>**Table 3.** Relaxivity values *r*₁, *r*₂ and *r*₂/*r*₁ of Gd(DOTA), and co-assembled P2-Gd(DOTAGA) *x* (*x* + 10, 15 or 20) at pH 5.5 and pH 11, at 7 T, 293 K</caption><thead><tr><th></th><th><i>r</i><sub>1</sub> (mM<sup>-1</sup>·s<sup>-1</sup>)</th><th><i>r</i><sub>2</sub> (mM<sup>-1</sup>·s<sup>-1</sup>)</th><th><i>r</i><sub>2</sub>/<i>r</i><sub>1</sub></th></tr></thead><tbody><tr><td>Gd(DOTA) (Dotarem)</td><td>5.3</td><td>5.5</td><td>1.0</td></tr><tr><td>pH = 5.5</td><td></td><td></td><td></td></tr><tr><td>P2-Gd(DOTAGA)10</td><td>13.6</td><td>14.5</td><td>1.1</td></tr><tr><td>P2-Gd(DOTAGA)15</td><td>12.1</td><td>14.2</td><td>1.2</td></tr><tr><td>P2-Gd(DOTAGA)20</td><td>11.0</td><td>14.0</td><td>1.3</td></tr><tr><td>pH = 11</td><td></td><td></td><td></td></tr><tr><td>P2-Gd(DOTAGA)10</td><td>2.2</td><td>18.2</td><td>8.4</td></tr><tr><td>P2-Gd(DOTAGA)15</td><td>4.0</td><td>19.4</td><td>4.8</td></tr><tr><td>P2-Gd(DOTAGA)20</td><td>3.8</td><td>20.3</td><td>5.4</td></tr></tbody></table>

Standard deviation values is ±0.2 mM<sup>-1</sup>·s<sup>-1</sup>. Adapted from Ref. [47].

However, the results indicate a decrease in the *r*₁ value from monomeric to co-assembled form, in the range similar to that of Gd(DOTA). On the other hand, both *r*₂ and *r*₂/*r*₁ increased by a factor of 4 to 7. The notable increase in *r*₂/*r*₁ is typical of a nanopartic- ular relaxivity behavior [60] where the outer sphere

contribution becomes predominant, due to mag- netic susceptibility effects induced by high molec- ular weight scaffold of nanoparticle. The increase in *r*₂/*r*₁ value obtained for the co-assembled P2- Gd(DOTAGA) indicates a clear nanoparticolar mag- netic behavior.
The decrease in r₁ could be explained by the fact that relaxivity values not only depend on the rotational correlation time, but also on other factors such as the exchange rate of bulk water molecules with the Gd center [60]. As the Gd complex is not functionalized at the extreme end of the peptide, and is less accessible to water molecules in its nanoparticular form, the interaction with the water molecules could be reduced. Furthermore, the MRI analysis was performed in this study under a high field (7 T). Van Bochove et al. studied the impact of magnetic field intensity, either 1.41 T or 6.3 T, on the relaxivity values of a micelle made of Gd(DTPA)-bis(stearylamide) [73]. They determined a significant difference in r₁ values, i.e., r₁ = 11.8 mM⁻¹·s⁻¹ and 4.5 mM⁻¹·s⁻¹, at 1.41 T and 6.3 T, respectively. Furthermore, they measured equivalent r₁ values as for the Gd(DTPA)-bis(stearylamide) monomer and an increased r₂ value of 13.0 mM⁻¹·s⁻¹ at 6.3 T. Thus, the values obtained in this study are coherent with the literature. They confirm the co-assembly of the peptide-conjugate mixtures and are promising for the use of these nanostructurations for MRI imaging, when employing a lower magnetic field (1 T) for T1 contrast, but remain efficient at high magnetic field (7 T) for T2 contrast.

To enhance r₁ relaxivity, different improvements of the design of such contrast agents could be envisaged (1) by the use of a linker between the peptide and Gd(DOTAGA), or the conjugation of the complex at the extremity of the sequence, to make it more accessible to water molecules in bulk or, (2) the use of higher functionalization rates to generate higher P2-Gd(DOTAGA)/ P2 ratio, to increase the amount of Gd to the contrast agent. Nevertheless, these results are very promising for the development of self-assembled peptide-based MRI contrast agents, which could be exploited further for theranostic applications.

## 7. Conclusion

Peptide self-assembly nanostructures are promising biocompatible materials for theranostics. Their simultaneous use as intelligent systems for targeted and controlled drug delivery system and as an imaging probe for diagnostics is significant for the development of personalized medicine. However, many challenges remain in the design and characterization

of such nanoobjects, and a deeper understanding of the interactions involved in self-assemblies is necessary for better control of their formation and further use for in vivo applications. Moreover, the functionalization of peptide sequences for theranostic applications needs to be optimized to maintain stable self-assembly and the desired imaging properties.

This synergistic multidisciplinary investigation enabled the development of syntheses and characterization methods that facilitate access to peptide sequences capable of self-assembling into nanostructures. The peptide sequences were designed to combine the expected properties for theranostic applications: (1) self-assembly for efficient drug encapsulation and biodistribution; (2) pH-sensitive self-assembly for drug delivery under a pH modification in the environment of cancer cells; (3) a receptor-targeting motif for specific and controlled delivery of the active ingredient to tumors; (4) accessible functions for further functionalization with a contrast agent for diagnosis. The simple, low time- and reactant-consuming protocol developed in flow chemistry and optimized with CE-ESI-MS, for sequence identification and purity, allowed to generate sequences that could be further used without any purification step. The efficient functionalization of these peptide sequences with an MRI probe optimized with CE-ESI-MS characterization allowed to generate mixtures of non-functionalized and functionalized peptides, that could be directly complexed with Gd(DOTAGA) and employed without purification for self-assembly or co-assembly formulations. Furthermore, a deep understanding of the mechanisms involved in peptide self-assembly could be obtained through the combination of analytical and physical methods, proving the obtainment of physicochemical properties of interest in the fields of diagnostics and therapy. The physicochemical characterization of the self-assemblies or co-assemblies of the peptide mixtures proved the efficient formulation of stable nanorods, with rapid kinetics and dimensions of 30 nm length and 7 nm diameter, due to β-sheet interactions. The nanostructurations preserved the RGD motif on the surface for further efficient targeting and were demonstrated promising for MRI imaging when employing classical magnetic fields for medical diagnosis.

These results enrich the overall understanding of
such formulations of theranostic applications. Areas for improvement were identified by deep characterizations, that promote the design of new sequences in a rational and efficient way, to combine smart and targeted drug delivery and imaging properties for the nanostructures obtained from peptide building blocks formulation.

Declaration of interests

The authors do not work for, advise, own shares in, or receive funds from any organization that could benefit from this article, and have no affiliations other than their research organizations.

Acknowledgments

The authors acknowledge the financial support provided by CNRS MITI Défi Organisation (AAP 2021, Pepthera) and by the IPGG Microfluidique Carnot Institute (Call 2020, PSL: C21-14-2021-033). They would like to thank: the NMR platform at Chimie ParisTech PSL for NMR analysis; the MRI Platform at SEISAD, Chimie ParisTech PSL and PIV LIOPA U Paris Cité for the MRI experiments; the MS3U at Sorbonne Université for the HRMS and MS/MS analyses; Mickaël Tharaud, from PARI platform at the Institut Physique du Globe de Paris, for ICP-MS analysis; Benoit Caron and Julie Noël, from the platform at Sorbonne Université for ICP-OES analysis; Charlotte Izabelle and Bruno Saubamea, Plateforme d'Imagerie Cellulaire et Moléculaire (PICMO), Université Paris Cité, for TEM and cryo-TEM images.

References

[1] S. R. Tracey, P. Smyth, C. J. Barelle and C. J. Scott, *Biochem. Soc. Trans.* **49** (2021), pp. 2253–2269.

[2] X. Shan, X. Gong, J. Li, J. Wen, Y. Li and Z. Zhang, *Acta Pharm. Sin. B* **12** (2022), pp. 3028–3048.

[3] C. Zhang, L. Yan, X. Wang, S. Zhu, C. Chen, Z. Gu and Y. Zhao, *Nano Today* **35** (2020), article no. 101008.

[4] M. S. Muthu, D. T. Leong, L. Mei and S.-S. Feng, *Theranostics* **4** (2014), pp. 660–677.

[5] S. Mura and P. Couvreur, *Adv. Drug Deliv. Rev.* **64** (2012), pp. 1394–1416.

[6] W. Poon, Y.-N. Zhang, B. Ouyang, B. R. Kingston, J. L. Y. Wu, S. Wilhelm and W. C. W. Chan, *ACS Nano* **13** (2019), pp. 5785–5798.

[7] D. Tesauro, A. Accardo, C. Diaferia, V. Milano, J. Guillon, L. Ronga and F. Rossi, *Molecules* **24** (2019), article no. 351.

[8] L. Lu, V. T. Duong, A. O. Shalash, M. Skwarczynski and I. Toth, *Vaccines* **9** (2021), article no. 563.

[9] Z. Li, Y. Zhu and J. B. Matson, *ACS Appl. Bio Mater.* **5** (2022), pp. 4635–4651.

[10] J. Yang, H.-W. An and H. Wang, *ACS Appl. Bio Mater.* **4** (2021), pp. 24–46.

[11] C. Diaferia, E. Gianolio and A. Accardo, *J. Pept. Sci.* **25** (2019), article no. e3157.

[12] V. B. Kumar, B. Ozguney, A. Vlachou, Y. Chen, E. Gazit and P. Tamamis, *J. Phys. Chem. B* **127** (2023), pp. 1857–1871.

[13] Y. Wang, X. Zhang, K. Wan, N. Zhou, G. Wei and Z. Su, *J. Nanobiotechnol.* **19** (2021), article no. 253.

[14] I. Kim, S.-M. Jin, E. H. Han, E. Ko, M. Ahn, W.-Y. Bang, J.-K. Bang and E. Lee, *Biomacromolecules* **18** (2017), pp. 3600–3610.

[15] I. Kim, E. H. Han, J. Ryu, J.-Y. Min, H. Ahn, Y.-H. Chung and E. Lee, *Biomacromolecules* **17** (2016), pp. 3234–3243.

[16] C. Zhao, H. Chen, F. Wang and X. Zhang, *Colloids Surf. B: Biointerfaces* **208** (2021), article no. 112040.

[17] C. P. Gordon, *Org. Biomol. Chem.* **16** (2018), pp. 180–196.

[18] J. Liang, W.-L. Wu, X.-D. Xu, R.-X. Zhuo and X.-Z. Zhang, *Colloids Surf. B* **114** (2014), pp. 398–403.

[19] M. Ko, A. Quiñones-Hinojosa and R. Rao, *Cancer Metastasis Rev.* **39** (2020), pp. 519–534.

[20] F. Tagliaro, G. Manetto, F. Crivellente and F. P. Smith, *Forens. Sci. Int.* **92** (1998), pp. 75–88.

[21] Z. P. Gates and N. Hartrampf, *Pept. Sci.* **112** (2020), article no. e24198.

[22] I. M. Mándity, B. Olasz, S. B. Ötvös and F. Fülöp, *Chem-SusChem* **7** (2014), pp. 3172–3176.

[23] E. Kaiser, R. L. Colescott, C. D. Bossinger and P. I. Cook, *Anal. Biochem.* **34** (1970), pp. 595–598.

[24] E. T. Sletten, M. Nuño, D. Guthrie and P. H. Seeberger, *Chem. Commun.* **55** (2019), pp. 14598–14601.

[25] A. J. Mijalis, D. A. Thomas, M. D. Simon, A. Adamo, R. Beaumont, K. F. Jensen and B. L. Pentelute, *Nat. Chem. Biol.* **13** (2017), pp. 464–466.

[26] C. Li, A. J. Callahan, K. S. Phadke, et al., *ACS Cent. Sci.* **8** (2022), pp. 205–213.

[27] C. Li, A. J. Callahan, M. D. Simon, et al., *Nat. Commun.* **12** (2021), article no. 4396.

[28] G. A. Acosta, M. del Fresno, M. Paradis-Bas, M. Rigau-DeLlobet, S. Côté, M. Royo and F. Albericio, *J. Pept. Sci.* **15** (2009), pp. 629–633.

[29] W. Wang, Y. Huang, J. Liu, et al., *Lab on a Chip* **11** (2011), pp. 929–935.

[30] A. Stolz, K. Jooß, O. Höcker, J. Römer, J. Schlecht and C. Neusüß, *Electrophoresis* **40** (2019), pp. 79–112.

[31] K. J. Rosnack, J. G. Stroh, D. H. Singleton, B. C. Guarino and G. C. Andrews, *J. Chromatogr. A* **675** (1994), pp. 219–225.

[32] C. Miller and J. Rivier, *J. Pept. Res.* **51** (1998), pp. 444–451.

[33] M. Hamdan, O. Curcuruto, S. Vigano and P. Rovero, *Rapid Commun. Mass Spectrom. RCM* **10** (1996), pp. 1128–1132.

[34] F. P. Gomes and J. R. Yates, *Mass Spectrom. Rev.* **38** (2019), pp. 445–460.

[35] J. Piestansky, P. Barath, P. Majerova, J. Galba, P. Mikus, B. Kovacech and A. Kovac, *J. Pharm. Biomed. Anal.* **189** (2020), article no. 113449.
[36] M. D. Cortez-Díaz, F. d'Orlyé, S. Gutierrez-Granados, L. M. de Leon-Rodriguez and A. Varenne, *Anal. Biochem.* **502** (2016), pp. 8–15.

[37] A. Am, M. E. Faccio, M. Pinvidic, et al., *J. Chromatogr. A* **1713** (2024), article no. 464496.

[38] S. Zhang, Z. Amso, L. M. De Leon Rodriguez, H. Kaur and M. A. Brimble, *J. Nat. Prod.* **79** (2016), pp. 1769–1774.

[39] P. W. R. Harris and M. A. Brimble, *Pept. Sci.* **100** (2013), pp. 356–365.

[40] E. I. Vrettos, N. Sayyad, E. M. Mavrogiannaki, et al., *RSC Adv.* **7** (2017), pp. 50519–50526.

[41] S. Fuse, Y. Otake and H. Nakamura, *Chem. – Asian J.* **13** (2018), pp. 3818–3832.

[42] Z. Zhou and Z.-R. Lu, *WIREs Nanomed. Nanobiotechnol.* **5** (2013), pp. 1–18.

[43] B. Todaro, E. Ottalagana, S. Luin and M. Santi, *Pharmaceutics* **15** (2023), article no. 1648.

[44] L. Carmès, M. Banerjee, P. Coliat, S. Harlepp, X. Pivot, O. Tillement, F. Lux and A. Detappe, *Adv. Ther.* **6** (2023), article no. 2300019.

[45] M. H. Stenzel, *ACS Macro Lett.* **2** (2013), pp. 14–18.

[46] J. M. J. M. Ravasco, H. Faustino, A. Trindade and P. M. P. Gois, *Chem. – Eur. J.* **25** (2019), pp. 43–59.

[47] A. Am, F. d'Orlyé, L. Trapiella-Alfonso, C. Lescot, B.-T. Doan and A. Varenne, *J. Chromatogr. A* submitted.

[48] N. Brown, P. Rocchi, L. Carmès, et al., *Theranostics* **13** (2023), pp. 4711–4729.

[49] J. F. Desreux, E. Merciny and M. F. Loncin, *Inorg. Chem.* **20** (1981), pp. 987–991.

[50] G. Tircsó, E. Tircsóné Benyó, Z. Garda, et al., *J. Inorg. Biochem.* **206** (2020), article no. 111042.

[51] S. D. Fontaine, R. Reid, L. Robinson, G. W. Ashley and D. V. Santi, *Bioconjug. Chem.* **26** (2015), pp. 145–152.

[52] X. Yang, L. Ma, K. Lu and D. Zhao, *Protein J.* **43** (2024), pp. 464–476.

[53] R. Mu, D. Zhu, S. Abdulmalik, S. Wijekoon, G. Wei and S. G. Kumbar, *Bioact. Mater.* **35** (2024), pp. 181–207.

[54] A. Am, L. Trapiella Alfonso, C. Izabelle, B. Saubamea, B.-T. Doan, F. d'Orlyé and A. Varenne, *Anal. Bioanal. Chem.* (2024).

[55] J. S. Nowick, *Acc. Chem. Res.* **41** (2008), pp. 1319–1330.

[56] S. R. K. Ainavarapu, J. Brujić, H. H. Huang, et al., *Biophys. J.* **92** (2007), pp. 225–233.

[57] J. Wang, S. Han, G. Meng, H. Xu, D. Xia, X. Zhao, R. Schweins and J. R. Lu, *Soft Matter* **5** (2009), pp. 3870–3878.

[58] A. Hawe, W. L. Hulse, W. Jiskoot and R. T. Forbes, *Pharm. Res.* **28** (2011), pp. 2302–2310.

[59] Y.-D. Xiao, R. Paudel, J. Liu, C. Ma, Z.-S. Zhang and S.-K. Zhou, *Int. J. Mol. Med.* **38** (2016), pp. 1319–1326.

[60] A. S. Merbach, L. Helm and É. Tóth, *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging* (A. Merbach, L. Helm and É. Tóth, eds.), John Wiley & Sons: New Jersey, 2013.

[61] S. Daksh, A. Kaul, S. Deep and A. Datta, *J. Inorg. Biochem.* **237** (2022), article no. 112018.

[62] S. Chen, L. An and S. Yang, *Molecules* **27** (2022), article no. 4573.

[63] C. Corot and D. Warlin, *Rev. Nanomed. Nanobiotechnol.* **5** (2013), pp. 411–422.

[64] G. W. Bourne and J. M. Trifaró, *Neuroscience* **7** (1982), pp. 1615–1622.

[65] J. Davies, P. Siebenhandl-Wolff, F. Tranquart, P. Jones and P. Evans, *Arch. Toxicol.* **96** (2022), pp. 403–429.

[66] A. Ghosh, M. Haverick, K. Stump, X. Yang, M. F. Tweedle and J. E. Goldberger, *J. Am. Chem. Soc.* **134** (2012), pp. 3647–3650.

[67] A. Koudrina and M. C. DeRosa, *ACS Omega* **5** (2020), pp. 22691–22701.

[68] L. Manzoni, L. Belvisi, D. Arosio, et al., *ChemMedChem* **7** (2012), pp. 1084–1093.

[69] L. Manzoni, L. Belvisi, D. Arosio, et al., *ChemMedChem* **4** (2009), pp. 615–632.

[70] P. Caravan, B. Das, S. Dumas, et al., *Angew. Chem. Int. Ed Engl.* **46** (2007), pp. 8171–8173.

[71] P. Caravan and Z. Zhang, *Eur. J. Inorg. Chem.* **2012** (2012), pp. 1916–1923.

[72] L. S. Arias, J. P. Pessan, A. P. M. Vieira, T. M. T. de Lima, A. C. B. Delbem and D. R. Monteiro, *Antibiotics* **7** (2018), article no. 46.

[73] S. Anjum, M. Hashim, S. A. Malik, M. Khan, J. M. Lorenzo, B. H. Abbasi and C. Hano, *Cancers* **13** (2021), article no. 4570.